The mean time of HCC development after anti-viral treatment was 4.14 years (SD: 2.63), with patients having significantly higher age (57.87 ± 8.30 years, p = 0.0087), FIB-4 > 3.25 score proportion (p < 0.0001), AFP (0.0063), AST (p < 0.0001), ALT (p = 0.0008), and GGT levels (p = 0.0004), but lower HCV viral loads (p = 0.0494), and platelet count (p < 0.0001) than the group without HCC development (Table 1). Here, AFP is linked to hepatocellular carcinoma.